Efficient and safe glycaemic control with basal-bolus insulin therapy during fasting periods in hospitalized patients with type 2 diabetes using decision support technology: A post hoc analysis.
Daniel A HochfellnerRaphael RainerHaris ZikoFelix AbererAmra SimicKatharina M LichteneggerPeter BeckKlaus DonsaThomas R PieberFriedrich M FruhwaldAlexander R RosenkranzLars-Peter KamolzPetra M BaumannJulia K MaderJohannes PlankPublished in: Diabetes, obesity & metabolism (2021)
When using well-titrated basal-bolus insulin therapy in hospitalized patients with type 2 diabetes, the basal insulin dose does not require adjustment during fasting periods to achieve safe glycaemic control, provided meal-related bolus insulin is omitted and correction bolus insulin is tailored to glucose levels.